British supermarket chain Sainsbury's and drugstore chain Boots recalled counterfeit Colgate Cavity Protectiontoothpaste in 100 mL cartons, the companies say. Colgate-Palmolive says Dec. 24 that no adverse events linked to the products were reported and the counterfeits were limited to the two U.K. chains. Sainsbury's says it asked customers to return the toothpaste for a full refund and is investigating "how this has occurred so that we can prevent it from happening again." Colgate-Palmolive warned U.S. consumers in June 2007 about South Africa-made counterfeit toothpaste that may have contained diethylene glycol (1"The Tan Sheet" June 18, 2007, In Brief). The firm says tests found no evidence of DEG in the current batch of fakes
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
